(UroToday.com) Pembrolizumab, an anti-PD-1 antibody, has antitumor activity as monotherapy in patients with heavily pre-treated, PD-L1 positive advanced prostate cancer as well as mCRPC patients regardless of PD-L1 expression status. KEYNOTE-365 is a 4-cohort study evaluating the combination of pembrolizumab in combination with multiple agents, as shown below. Results from Cohort B, the combination of pembrolizumab with docetaxel and prednisone, were previously presented at ESMO 2020 after a median follow-up of 20 months. In this presentation, Dr. Appleman shared updated data with a median time of follow-up of 32.4 months.  The study schema is shown below.